within Pharmacolibrary.Drugs.ATC.L;

model L01AA03_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 2.8333333333333336e-07,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01AA03_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Melphalan is an alkylating agent used in the treatment of multiple myeloma and ovarian cancer. It works by cross-linking DNA, thus inhibiting DNA and RNA synthesis and leading to cell death. It is still approved and in clinical use, particularly for hematological malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult patients after oral administration of melphalan for multiple myeloma.</p><h4>References</h4><ol><li><p>Alberts, DS, et al., &amp; Moon, TE (1979). Oral melphalan kinetics. <i>Clinical pharmacology and therapeutics</i> 26(6) 737–745. DOI:<a href=&quot;https://doi.org/10.1002/cpt1979266737&quot;>10.1002/cpt1979266737</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/498715/&quot;>https://pubmed.ncbi.nlm.nih.gov/498715</a></p></li><li><p>Boros, L, et al., &amp; Hickox, DE (1990). Pharmacokinetics of very high-dose oral melphalan in cancer patients. <i>American journal of clinical oncology</i> 13(1) 19–22. DOI:<a href=&quot;https://doi.org/10.1097/00000421-199002000-00006&quot;>10.1097/00000421-199002000-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2305718/&quot;>https://pubmed.ncbi.nlm.nih.gov/2305718</a></p></li><li><p>Woodhouse, KW, et al., &amp; Rawlins, MD (1983). The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. <i>European journal of clinical pharmacology</i> 24(2) 283–285. DOI:<a href=&quot;https://doi.org/10.1007/BF00613833&quot;>10.1007/BF00613833</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6840181/&quot;>https://pubmed.ncbi.nlm.nih.gov/6840181</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01AA03_1;
